How can I identify patients who would benefit from ruxolitinib cream?
Assistant Professor, Director of Center for Eczema and Itch
Northwestern University Feinberg School of Medicine
A common question I get is who's the right patient when it comes to ruxolitinib cream? Well, there's a couple of things you're looking for in a lot of this is based on the FDA indication and exactly the way that the trials were designed. So you're looking for that patient who's mild to moderate and typically you can have a body surfacing area of involvement somewhere between 3 and 20% and that simply just comes from the actual trials themselves. In the real world, patient times are often coming in, having used topical corticosteroids or topical calcineurin inhibitors, and depending on insurance approval, that may be something that you're looking for too. But really you're thinking about that patient that isn't getting control through their normal therapies, and really is looking forward not only to lesional control, but also control their itch as well.
Dr Raj Chovatiya addresses the question of how to identify a patient who would benefit from ruxolitinib cream. He explains that the right patients for this treatment are those with mild to moderate symptoms and a body surface area of involvement between 3% and 20%. These criteria are based on the FDA indication and clinical trial design.
In real-world scenarios, patients seeking ruxolitinib cream often have already tried topical corticosteroids or topical calcineurin inhibitors, and a key factor to consider is if patients have not experienced adequate control of their symptoms with these other therapies. The ideal candidate for ruxolitinib cream is someone who desires not only lesional control but also itch control.
Overall, identifying patients who would benefit from ruxolitinib cream involves assessing the severity of their condition, the affected body surface area, and the inadequacy of previous treatments in controlling their symptoms.
- The key question is: "Who is the right patient for ruxolitinib cream?"
- The ideal patient profile includes those with mild to moderate symptoms
- Patients typically have a body surface area of involvement between 3% and 20%
- Patient candidates have often already tried topical corticosteroids or topical calcineurin inhibitors
- The target patient is someone who hasn't achieved sufficient control with other therapies
- The desired outcome is not only lesional control, but also itch relief